SciSparc SPRC
NASDAQ SPRC
$0.38 -0.03 (-7.87%)
As of: Nov 10, 2026 · 12:24 PM EST

SciSparc (SPRC) Exchange Rate Effect (2016 - 2018)

Updated

SciSparc's Exchange Rate Effect was $9,000 in FY2019, down 97.0% from $301,000 in FY2018.

Analysis

SciSparc (SPRC) Exchange Rate Effect (2016 - 2018) Analysis & Trends

From FY2015 onward, SciSparc has reported Exchange Rate Effect for 5 years.

  • Exchange Rate Effect shows a four-year compound annual growth rate of -41.5% (FY2015 to FY2019).
  • Annual Exchange Rate Effect has moved between -$527,000 (FY2017) and $301,000 (FY2018) over five years.
  • Per Business Quant data, Exchange Rate Effect in earlier years was $301,000 in FY2018, -$527,000 in FY2017, -$8,000 in FY2016 and $77,000 in FY2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FX Effect (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 56.00 Mn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 10.00 Mn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -6.00 Mn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -46.00 Mn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -18.00 Mn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -4.00 Mn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 1.00 Mn
10 SciSparc 49,990.67 -14.39 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 600,000.00
Sep 30, 2018 -607,000.00
Jun 30, 2018 218,000.00
Mar 31, 2018 90,000.00
Dec 31, 2017 -162,000.00
Sep 30, 2017 81,000.00
Jun 30, 2017 -453,000.00
Mar 31, 2017 7,000.00
Dec 31, 2016 -25,000.00
Sep 30, 2016 17,000.00
Jun 30, 2016 -25,000.00
API Access

SciSparc Exchange Rate Effect API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=exchange-rate-effect&ticker=SPRC&period=max&api_key=YOUR_API_KEY